Generating a broad portfolio of novel agents with best-in-class potential.

Development Pipeline

Driving meaningful advances to address chronic inflammation.

We’re committed to evolving immunology, with a pipeline that includes programs specifically targeted to address inflammatory diseases demonstrating clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell and T-cell activity shows promise in multiple established patient populations.

Program
Target
Indication
  • Discovery
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
EVO756
MRGPRX2
Chronic Spontaneous Urticaria Atopic Dermatitis/Inflammatory Itch Other Indications
PKCϴ Inhibitor
PKCϴ
Psoriasis Inflammatory Bowel Disease Other Indications

Program
Target
EVO756
MRGPRX2
Indication
Stage
Chronic Spontaneous Urticaria
Atopic Dermatitis/Inflammatory Itch
Other Indications
Phase 1
Phase 1
Pre-Clinical
Pre-Clin.
Program
Target
PKCϴ Inhibitor
PKCϴ
Indication
Stage
Psoriasis
Inflammatory Bowel Disease
Other Indications
Pre-Clinical
Pre-Clin.
Pre-Clinical
Pre-Clin.
Pre-Clinical
Pre-Clin.

Learn about our ongoing clinical trials for our investigational therapies.

View Clinical Trials